12 completed. 10 Phase 1, 2 Phase 2.
By phase and status
Follow AZD5004: new trials by email Literature Review of AZD5004 trials Research Report on AZD5004
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
AZD5004, Mitiglinide, Pioglitazone - Healthy Participants | Phase 1 | Completed | AstraZeneca | 32 | 2026-03-13 | 2026-07-13 |
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years
AZD5004 - Healthy Participants | Phase 1 | Completed | AstraZeneca | 65 | 2026-03-05 | 2026-06-10 |
A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus
AZD5004, Placebo - Obesity or Overweight, Type 2 Diabetes | Phase 1 | Completed | Eccogene | 45 | 2025-06-17 | 2025-12-23 |
A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants
AZD5004, Itraconazole, EE/LNG - Healthy Participants | Phase 1 | Completed | AstraZeneca | 51 | 2025-05-28 | 2026-02-03 |
A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations
AZD5004 - Healthy Participants | Phase 1 | Completed | AstraZeneca | 16 | 2025-05-22 | 2025-07-31 |
A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants
AZD5004, Rosuvastatin, Erythromycin - Healthy Participants | Phase 1 | Completed | AstraZeneca | 49 | 2025-05-06 | 2025-10-10 |
A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004
AZD5004 film-coated tablet, [14C]AZD5004 Solution for Infusion, [14C]AZD5004 Oral Solution - Healthy Participants | Phase 1 | Completed | AstraZeneca | 8 | 2025-03-06 | 2025-05-28 |
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
AZD5004 - Hepatic Impairment | Phase 1 | Completed | AstraZeneca | 33 | 2024-12-19 | 2025-10-15 |
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
AZD5004 - Renal Impairment | Phase 1 | Completed | AstraZeneca | 16 | 2024-12-17 | 2025-06-08 |
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
AZD5004, Placebo - Obesity or Overweight | Phase 2 | Completed | AstraZeneca | 310 | 2024-10-08 | 2025-12-18 |
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Placebo (placebo matching AZD5004 film-coated tablet), AZD5004, Semaglutide - Diabetes Mellitus, Type 2 | Phase 2 | Completed | AstraZeneca | 406 | 2024-10-08 | 2026-01-13 |
A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants
AZD5004, Placebo - Healthy Participants | Phase 1 | Completed | AstraZeneca | 31 | 2024-08-15 | 2025-03-17 |
Conditions studied
Diabetes Mellitus, Type 2 (8) · Obesity (7) · Overweight (2) · Renal Insufficiency (1)
Sponsors
AstraZeneca (11) · Eccogene (1)
Countries
United States (9) · Germany (3) · Japan (3) · United Kingdom (3) · Canada (2) · Australia (1) · China (1) · Hungary (1) · Poland (1) · Slovakia (1) · Spain (1) · Taiwan (1)
Top investigators
Prof Melanie Davies, MBChB MD (1) · Sharan Sidhu, MBChB, BAO, MRCS, MFPM (1)
Results publications
PMID 42259337, PMID 42259343